Mon, June 14, 2010
Sat, June 12, 2010
Fri, June 11, 2010
Thu, June 10, 2010
Wed, June 9, 2010
Tue, June 8, 2010
Mon, June 7, 2010
Sun, June 6, 2010
Sat, June 5, 2010
Fri, June 4, 2010
Thu, June 3, 2010
Wed, June 2, 2010
Tue, June 1, 2010
[ Tue, Jun 01st 2010 ]: Market Wire
Covidien???????????????????
Mon, May 31, 2010
Sat, May 29, 2010
Fri, May 28, 2010
Thu, May 27, 2010

AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. to-present-at-upcoming-investor-conferences.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

- Click to Lock Slider

LEXINGTON, Mass.--([ BUSINESS WIRE ])--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will present at the following investor conferences during the month of June:

  • June 9, at 8:00 a.m. ET a" 9th Annual Needham Healthcare Conference in New York City;
  • June 10, at 4:30 p.m. ET a" Jefferies 2010 Global Life Sciences Conference in New York City; and
  • June 15, at 2:30 p.m. PT a" Goldman Sachs 31st Annual Global Healthcare Conference in Los Angeles, CA.

Live webcasts of each presentation will be accessible through the Investors section of the companya™s website at [ www.amagpharma.com ]. Following each conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website for approximately two weeks.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. On June 30, 2009, AMAG received approval from the U.S. Food and Drug Administration to market Feraheme® (ferumoxytol) Injection for intravenous (IV) use for the treatment of iron deficiency anemia in adult chronic kidney disease patients. For additional company and product information, please visit [ www.amagpharma.com ].

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.